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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) affects 12.5 million worldwide. Vasopressin drives
cysts growth and in animal models can be suppressed through high water intake. A randomized controlled trial of ‘high’
versus ‘standard’ water intake in ADPKD is essential to determine if this intervention is beneficial. We conducted an ADPKD
patient survey to gain an understanding of current fluid intake practices and the design challenges of a randomized water
intake trial.
Methods: In collaboration with the PKD Charity, we developed and distributed an online survey to ADPKD patients over age
16 years and not on renal replacement therapy.
Results: Of the 2377 invited, 89 ADPKD patients completed the Survey of current water Intake practices in autosomal domi-
nant Polycystic kidney disease (SIPs) online questionnaire. Most were female (65, 73%) and white (84, 94%), with a median
age group of 45–49 years. The risk of contamination between treatment arms was highlighted by the survey as the majority
(70, 79%) routinely discussed ADPKD management with family despite only 17% sharing the same household. More partici-
pants reported drinking beyond thirst (65, 73%) than those actually indicating a daily fluid intake of>2 L (54, 61%). This dis-
crepancy emphasizes inaccuracies of fluid intake estimates and the requirement for objective methods of measuring water
intake. Overall, only 51% believed high water intake was beneficial, while 91% were willing to participate in research evalu-
ating this.
Conclusion: ADPKD poses unique design challenges to a randomized water intake trial. However, the trial is likely to be sup-
ported by the ADPKD community and could impact significantly on PKD management and associated healthcare costs.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the
most common inherited renal disease, affecting 12.5 million
people worldwide [1]. It accounts for 7% of incident adults com-
mencing renal replacement therapy in the UK [2]. ADPKD is
characterized by the relentless growth of cysts throughout the
kidneys, resulting in progressive kidney dysfunction over time.
Half of those affected require dialysis by 50 years of age. In the
early stages of the disease, there is compensatory hyper-
filtration by the remaining normal nephrons, preserving renal
excretory function. Over time, these mechanisms are over-
whelmed due to ongoing cyst growth causing compression, fib-
rosis and inflammation. This results in progressive renal
impairment [3].
Most cases are caused by mutations in the PKD1 or PKD2
genes, but in up to 15% of cases no genetic mutation is identi-
fied using currently available sequencing technology [1].
Although an autosomal dominant condition, the initial germ-
line mutation is accompanied by further somatic mutations
that cause a ‘second hit’ required for cystogenesis [4], together
with interactions with modifier genes and environmental fac-
tors. These are primarily responsible for phenotypic variability
even within families.
The pathogenic role of vasopressin in ADPKD has been shown
in previous studies [5, 6], and vasopressin receptor antagonists
have emerged as a novel treatment that slows PKD progression.
In the TEMPO3:4 trial, the V2 receptor antagonist tolvaptan
resulted in reduced growth in total kidney volume (TKV) com-
pared with placebo (2.8% versus 5.5% per year), and a lower rate
of worsening kidney function [7]. However, 23% discontinued the
drug due to side effects including aquaresis and liver toxicity.
Given that vasopressin release can be readily suppressed by
drinking beyond thirst [6, 8–10], it is possible that disease progres-
sion may similarly be slowed by high water consumption.
Animal studies of high water intake have been encouraging
[11]. In contrast, human data are limited and conflicting, with one
study showing potential harm [12]. Nonetheless, on this assump-
tion, many clinicians encourage ADPKD patients to increase their
daily water intake to 2–4 L. However, there is no existing evidence
to support the population-wide promotion of high water intake in
ADPKD. Against this background of uncertainty over the optimum
fluid consumption, Tong et al. reported survey data showing that
patients with ADPKD identify non-pharmacological interventions
such as fluid intake and diet as key research priorities [13].
There is an urgent need for trials to evaluate the optimal
hydration strategy in patients with ADPKD. We conducted a
survey of patients with ADPKD to inform the design of a
randomized feasibility trial of high versus standard water
intake. In this study, we considered potential barriers to, and
methodological issues involved in, conducting a water intake
trial in patients with PKD.
Materials and methods
We developed the Survey of current water Intake practices in
autosomal dominant Polycystic kidney disease (SIPs survey) with
the PKD Charity and patients with ADPKD. Draft questionnaires
were screened for suitability and clarity by a patient panel, and
amended as required before administration of the final survey.
The final version (see Supplementary data) was distributed
online via the PKD Charity website and on social media, and
included questions on demographics, family relationships with
particular reference to other affected family members, the extent
to which patients discussed their condition and treatments with
relatives, existing fluid consumption patterns, willingness to par-
ticipate in a hypothetical randomized water intake trial and will-
ingness to perform urine testing at home.
Participants were asked to report their estimated daily fluid
intake. Based on these estimates, participants were divided into
those with an intake>2 or2 L/day. Responses were compared
between the High Intake and Low Intake groups.
Data were reported as mean6 standard deviation or median
(interquartile range, IQR) as appropriate for their distribution,
unless otherwise specified. Categorical variables were compared
using Fisher’s exact test. All data were summarized and analysed
using Stata version 13 (Stata Corp., College Station, TX, USA).
Results
We carried out a consultation process including clinicians,
healthcare professionals, patients and methodologists in collab-
oration with the PKD Charity (http://pkdcharity.org.uk). We
identified several areas that could be fully or partly addressed
by directly surveying patients with ADPKD, including (i) willing-
ness to participate in clinical research, (ii) willingness to carry
out self-monitoring of urine parameters, (iii) existing water con-
sumption practices and willingness to deviate from this in a
randomized design and (iv) interaction and co-habitation with
affected relatives (potential for contamination of the control
arm). All ADPKD patients on the PKD Charity mailing list aged
16 years or older were eligible to participate in the SIPs survey.
Participant characteristics
We recorded responses from 89 people with ADPKD. Of these,
65 (73%) were female and 84 (94%) were Caucasian. The median
age group of participants was 45–49 years, with a median age
group of 30–34 years at diagnosis.
The majority of respondents (52, 58%) were employed; a fur-
ther 7 (8%) were students and 18 (20%) were retired; and 41
(46%) respondents completed the questionnaire online using a
desktop or laptop computer, while 26 (29%) used a smartphone
and 22 (25%) used a tablet computer.
Seventy-three (82%) participants reported as receiving their
medical care in secondary rather than primary care. The
median follow-up frequency was 12–17 months (Figure 1), while
only 11% (10/89) received their follow-up in primary care. The
remaining 7% did not provide a response to the question.
Fig. 1. Follow-up site and frequency of respondents. The majority of respond-
ents received follow-up at least every 18 months, 21% had follow-up more fre-
quently than every 6 months. Only 11% received follow-up in primary care.
2 | R. El-Damanawi et al.
Family relations. Seventy-one (80%) participants indicated that
they had affected family members. Of the remainder, 11 (12%)
reported no affected relatives and the remaining 7 (8%) did not
know. Importantly, the majority (70, 79%) reported discussing
their condition and treatment with affected family, despite only
15 participants (17%) sharing a home with them (Figure 2).
Current intake practices. There was wide variation in self-
reported fluid intake among participants (ranging<1.0 to>4.0 L/
day): 54 participants (61%) reported drinking>2 L/day (Figure 3).
However, 65 patients (74%) reported drinking beyond thirst, yet
18 (28%) of these estimated their fluid intake at <2.0 L daily.
We next compared responses between patients reporting
intake>2 L/day (the High Intake group) and those reporting 2
L/day (Low Intake group) as shown in Table 1. Significantly,
more patients in the High Intake group (47/54, 87%) reported
making an effort to drink beyond thirst compared with the Low
Intake group (18/35, 51%, P¼ 0.001). The proportion of partici-
pants reporting nocturia did not differ between the High Intake
and Low Intake groups [31/54 (57%) versus 22/35 (63%), P¼ 0.66].
A similar proportion of participants in the High Intake and Low
Intake groups declared a belief that high water intake was bene-
ficial [28/54 (52%) versus 17/35 (49%), P¼ 0.1].
Research participation and self-monitoring
A very high proportion of respondents (80, 92%) indicated a will-
ingness to participate in ADPKD research. Most respondents
indicated that, as part of research, they would undertake 24-h
(92%), spot (94%) or home urine testing (96%, Figure 4).
Discussion
The results of the SIPs survey showed that in this group of
ADPKD patients, respondents were highly motivated to partici-
pate in a water intake trial. They were also willing to collect 24-
h urine samples, carry out home urine monitoring and provide
blood samples. More than 9 in every 10 respondents expressed
a willingness to undergo a range of urine assessments, and this
willingness was not affected by the method of collection includ-
ing 24-h urine collection. The majority (82%) received follow-up
in secondary care.
The survey demonstrated a wide range of daily fluid intake
volumes, suggesting that many PKD patients do not currently
drink beyond thirst despite widely prevalent guidance from
healthcare professionals and via other media to drink large vol-
umes. We set a threshold for defining ‘high water intake’ of 2 L/
day based on previous data showing a urine osmolality of 344–
648 mOsm/kg in patients with PKD [8]. Given that the free water
clearance formula allows the estimation of the requisite fluid
intake to achieve a set urine osmolality, it follows that a patient
with a urine osmolality of 344 mOsm estimated from a collec-
tion of 1.2 L of urine (assuming insensible losses of 500 mL)
would have a requisite fluid intake of 2028 L to achieve a urine
osmolality of 270 mOsm/kg.
Fluid intake ¼ ðuOsmÞðuVolÞ
Target uOsm
þ Insensible Loss
It is therefore reasonable to accept 2 L as the lower limit of the
‘high water intake’ range.
Consistent with the wide distribution of fluid intake, only
half of respondents held the belief that high water intake was
beneficial, indicating equipoise at patient level. The discrepancy
between the proportion of patients ‘drinking beyond thirst’
(74%) and those reporting intake>2 L/day (61%) suggests that
patient estimates of fluid consumption are inaccurate.
Objective estimates of fluid intake are therefore important for
future studies.
Given the autosomal dominant inheritance of PKD, it is not
surprising that the majority of survey respondents had an
affected family member. However, despite only a small propor-
tion living in the same household, most (79%) regularly
Fig. 2. Responses to family relationship survey questions. The majority (80%)
knew an affected family member and discussed the management of the condi-
tion with them (79%), despite most (83%) living in different households.
Fig. 3. Estimated current daily fluid intake (L/day).There was a wide variation in
daily fluid intake; however, the majority (61%) reported an intake of 2 L/day
with only 4% drinking>4 L/day. The rest (39%) drank<2 L/day.
Table 1. Comparison of water intake practices in High and Low
Intake groups
Question
Low Intake High Intake
P-value(2 L/day) (%) (>2 L/day) (%)
Do you actively make an
effort to drink throughout
the day even when you
are not thirsty? (Yes)
51 87 0.001
(18/35) (47/54)
Do you get up at night to
pass urine? (Always/
Frequent)
63 57 0.660
(22/35) (31/54)
To what extent do you
believe drinking water
throughout the day can
slow down the progres-
sion of PKD? (Agree)
49 52 0.100
(17/35) (28/54)
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discussed their condition and its treatment with affected rela-
tives. This raises the possibility that in an open-label, parallel
group, randomized water intake trial, enrolling multiple mem-
bers of the same family may lead to contamination of the con-
trol arm. Thus, careful consideration is required when selecting
the randomization method for a water trial.
The strengths of our findings should be considered against
its limitations. The questionnaire was accessible online via the
Internet. The proportion of responders was low, and those who
responded were predominantly British, Caucasian and female.
Our results may therefore not be representative of male ADPKD
patients or those from other ethnic backgrounds, and should be
interpreted with caution. The low response rate (3.7%) is attrib-
utable to several factors: (i) invites were sent only once, given
that patients on the mailing list receive frequent requests for
surveys, (ii) we offered no incentive for participation and (iii) we
restricted participation to online platforms. Nevertheless, the
response rate was within the range reported from other online
surveys [14].
Since high water intake should suppress vasopressin pro-
duction, it may also slow the progression of ADPKD. Data from
animal studies are consistent with this hypothesis, showing
reduced cyst growth and slower decline in kidney function with
increased hydration in a variety of rodent models [11, 15]. A
number of small studies have looked at the impact of high
water intake on PKD in humans. Higashihara et al. [12] allocated
participants according to their preference to high (n¼ 18) and
free (n¼ 16) water intake. Although not statistically significant,
in the high intake group after 1 year the percentage change in
TKV increased (3.8–9.1% per year) and the estimated glomerular
filtration rate slope worsened (0.3 to 7.1 mL/min/1.73 m2). In
a pilot trial of 34 ADPKD patients [16], Amro et al. demonstrated
that randomization to low osmolar diet and high fluid intake
reduced plasma copeptin concentrations (a surrogate marker
for vasopressin) and urine osmolality.
In unselected chronic kidney disease patients, a high water
intake trial is ongoing and has achieved sufficient adherence to
a high water intake prescription to demonstrate separation
between trial arms [17]. In ADPKD, small studies suggest that
water intake can be sufficiently increased to suppress vasopres-
sin, rendering a large trial assessing renal outcomes feasible [12,
16, 18]. In a randomized pilot trial (PREVENT-ADPKD,
ACTRN12614001216606), 180 ADPKD patients will be assigned to
standard care or a high water intake prescription. The trial will
assess feasibility endpoint and change in TKV. In a randomized
feasibility trial (DRINK, NCT02933268), 50 ADPKD patients will
be assigned to high versus ad lib water intake to assess
feasibility, self-monitoring and treatment adherence. Together,
these trials will inform the design of a definitive water intake
trial in ADPKD. The SIPs survey data presented here provides
preliminary data on the potential feasibility and acceptability of
a high water intake trial in patients with ADPKD.
High water intake is an attractive intervention for ADPKD. It
is readily available, generally safe and required to sustain life. It
is likely to be suitable in patients excluded from or intolerant of
pharmacological therapies. However, given the effect of renal
impairment on water handling and conflicting data from exist-
ing literature, well-designed trials of high water intake in
ADPKD are urgently needed. The SIPs survey results are an
important first step towards achieving this goal.
Supplementary data
Supplementary data are available online at http://ckj.oxford
journals.org.
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